| Detected | Trial | Change |
|---|---|---|
| 2026-08-11 | NCT07112196 Visugromab in Cachexia International Trial |
Trial sites expanded: 56 -> 65 locations |
| 2026-07-30 | NCT07246863 Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of… |
Trial sites expanded: 25 -> 33 locations |
| 2026-07-22 | NCT07112196 Visugromab in Cachexia International Trial |
Trial sites expanded: 35 -> 56 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT07112196 | Visugromab in Cachexia International Trial | Cancer-associated Cachexia | Recruiting |
| Phase 2 | |||
| NCT07219459 | Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in… | Unresectable or Metastatic Hepatocellular Carcinoma | Recruiting |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of… | Metastatic Non-Squamous Non-Small Cell Lung Cancer | Recruiting |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of… | Metastatic Non-Squamous Non-Small Cell Lung Cancer | Recruiting |
| NCT06059547 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat… | Bladder Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients… | Solid Tumor, Adult | Active, Not Recruiting |